Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy
- PMID: 8617986
Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy
Abstract
Gene therapy offers a novel approach to treating human joint diseases such as rheumatoid arthritis. In the present study, we have used the retrovirus, MFG-IRAP, to transfer the human IL-1 receptor antagonist protein (IRAP) gene to rabbits' knees and have assessed its impact on inflammatory and chondrodestructive aspects of the acute phase of antigen-induced arthritis in these joints. Surprisingly, intra-articular expression of IRAP was three- to fivefold higher in arthritic knees than in nonarthritic knees, accumulating to levels of over 20 ng/knee in the highest expressing joints. This level of expression produced a marked chondroprotective effect but a milder anti-inflammatory one. Both the increased cartilage matrix catabolism and the inhibition of matrix synthesis that occur in antigen-induced arthritis were abrogated in the presence of the IRAP gene; the latter effect was particularly strong. Of the indices of inflammation that were examined, only leukocyte influx into the joint space was inhibited, and this effect declined with time. Concentrations of rabbit IL-1 were reduced by the IRAP gene, suggesting inhibition of an autocrine induction loop. These data demonstrate that the course of arthritic disease in the rabbit knee can be altered by genetic manipulation, thus encouraging the further development of gene treatments for human joint diseases.
Similar articles
-
Suppression of intra-articular responses to interleukin-1 by transfer of the interleukin-1 receptor antagonist gene to synovium.Gene Ther. 1994 Jan;1(1):64-9. Gene Ther. 1994. PMID: 7584062
-
Suppression of experimental osteoarthritis by adenovirus-mediated double gene transfer.Chin Med J (Engl). 2006 Aug 20;119(16):1365-73. Chin Med J (Engl). 2006. PMID: 16934183
-
Suppression of early experimental osteoarthritis by gene transfer of interleukin-1 receptor antagonist and interleukin-10.J Orthop Res. 2004 Jul;22(4):742-50. doi: 10.1016/j.orthres.2003.12.007. J Orthop Res. 2004. PMID: 15183429
-
Technology evaluation: MFG-IRAP, University of Pittsburgh.Curr Opin Mol Ther. 2000 Apr;2(2):216-20. Curr Opin Mol Ther. 2000. PMID: 11249645 Review.
-
Interleukin-1 receptor antagonist gene therapy for arthritis.Curr Opin Mol Ther. 1999 Aug;1(4):454-7. Curr Opin Mol Ther. 1999. PMID: 11713759 Review.
Cited by
-
A comparative study of the inhibitory effects of interleukin-1 receptor antagonist following administration as a recombinant protein or by gene transfer.Arthritis Res Ther. 2003;5(5):R301-9. doi: 10.1186/ar795. Epub 2003 Aug 1. Arthritis Res Ther. 2003. PMID: 12932294 Free PMC article.
-
Gene therapy of the rheumatic diseases: 1998 to 2008.Arthritis Res Ther. 2009;11(1):209. doi: 10.1186/ar2563. Epub 2009 Jan 30. Arthritis Res Ther. 2009. PMID: 19232068 Free PMC article. Review.
-
Gene therapy for rheumatoid arthritis.Springer Semin Immunopathol. 1998;20(1-2):197-209. doi: 10.1007/BF00832007. Springer Semin Immunopathol. 1998. PMID: 9836377 Review. No abstract available.
-
Joint inflammation and cartilage destruction may occur uncoupled.Springer Semin Immunopathol. 1998;20(1-2):149-64. doi: 10.1007/BF00832004. Springer Semin Immunopathol. 1998. PMID: 9836374 Review.
-
Autoimmunity, immunologic tolerance, and gene therapy.Immunol Res. 1998;17(1-2):33-40. doi: 10.1007/BF02786428. Immunol Res. 1998. PMID: 9479565 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical